2bind
2bind GmbH is a Regensburg, Germany-based biopharma CRO providing preclinical molecular interaction analysis services for small molecule drug discovery and antibody development, serving biotech and pharmaceutical clients globally with an integrated assay platform spanning MST, SPR-like, cell-based kinetics, and formulation development.
- Company typePrivate
- Founded2017
- HeadquartersRegensburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What 2bind does
2bind GmbH is a privately-held biopharma Contract Research Organization (CRO) headquartered in Regensburg, Germany, specializing in molecular interaction analysis for preclinical drug discovery. Founded in 2011 and strategically relaunched in 2017, the company serves biotech and pharmaceutical innovators across small molecule drug discovery (protein purification, hit identification, hit validation, hit-to-lead optimization) and antibody development (screening, lead selection, developability assessment, preformulation, and stability). Its service portfolio is powered by an integrated assay platform spanning MicroScale Thermophoresis (MST), Gradient Confocal Interferometry (GCI), Biolayer Interferometry (BLI), Isothermal Titration Calorimetry (ITC), Spectral Shift/TRIC, Dynamic Light Scattering (DLS), nanoDSF, flow cytometry, and proprietary Single-Cell Interaction Cytometry (scIC) on the heliXcyto platform, supported by BSL1/BSL2 certified cell culture laboratories.
The company operates a project-based professional services model with milestone-based pricing, quote-based engagement, and rapid turnaround times (1-2 days up to two weeks). Revenue also derives from product sales of FORMOscreen® (a 96-well buffer screening plate) through its e-commerce shop and a manufacturing/distribution partnership with Jena Bioscience. Distribution is direct via senior scientist-led sales, with no third-party resellers for core CRO services. 2bind holds certified service provider status with NanoTemper, Wyatt Technologies, and Dynamics Biosensors, and operates under an ISO 9001:2015 certified quality management system.
2bind has scaled its commercial footprint through multiple BMBF-funded research consortia (cumulative ~€3.15M in grants for GATarget antibiotic resistance and HIVacToGC HIV vaccine programs), strategic partnerships with Assay.Works, Jena Bioscience, and Fraunhofer ITEM, and entry into the CNATM nucleic acid therapeutics consortium. Leadership is split between Co-CEOs Dr. Maximilian Plach (Operations, Development, Technology) and Dr. Cosimo Kropp (Sales, Business Development, Finance), with founder Prof. Dr. Gernot Längst and Prof. Dr. Ralf Wagner (Geneart AG founder) as advisors.
2bind firmographics
Firmographics- Name
- 2bind
- Legal name
- 2bind GmbH
- Website
- https://2bind.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 2bind GmbH is a Regensburg, Germany-based biopharma CRO providing preclinical molecular interaction analysis services for small molecule drug discovery and antibody development, serving biotech and pharmaceutical clients globally with an integrated assay platform spanning MST, SPR-like, cell-based kinetics, and formulation development.
- Ownership category
- akta.pro rank
2bind industry classification
Industry- Product category
- Biopharma Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where 2bind is headquartered
LocationHeadquarters
- HQ city
- Regensburg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
2bind business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Services: Project-based CRO services for biotech and pharma clients covering small molecule drug discovery (protein purification, hit identification, validation, hit-to-lead optimization) and antibody development (screening, lead selection, developability, preformulation). Billed per project with milestone-based architecture.
- FORMOscreen® Product Sales: Sale of FORMOscreen® 96-well buffer plates for antibody formulation screening. Distributed through own shop and Jena Bioscience.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
2bind product offering
Product offeringCore offering
2bind is a preclinical biopharma Contract Research Organization (CRO) providing end-to-end and stand-alone biophysical characterization services for small molecule drug discovery (protein purification, hit identification, hit validation, hit-to-lead optimization) and antibody development (screening, lead selection, developability, preformulation, storage stability). Services leverage proprietary biophysical platforms including Single-Cell Interaction Cytometry (scIC), MST, GCI, BLI, ITC, DLS, nanoDSF, and Spectral Shift, supported by BSL-1/BSL-2 cell culture laboratories and ISO 9001:2015 quality management. The company also sells FORMOscreen® pre-made buffer plates directly and via Jena Bioscience.
Product overview
2bind is a Contract Research Organization (CRO) providing preclinical biopharma services for Small Molecule Drug Discovery and Antibody Development. The company offers both integrated service portfolios (end-to-end project support) and stand-alone services (targeted analyses). Key products include FORMOscreen® (a 96-well buffer screening plate) and Quick'n'Tidy™ buffer screen. The service offering is powered by multiple technology platforms including MicroScale Thermophoresis (MST), Gradient Confocal Interferometry (GCI), Biolayer Interferometry (BLI), Isothermal Titration Calorimetry (ITC), Spectral Shift/TRIC, Single-Cell Interaction Cytometry (scIC) on the heliXcyto platform, Dynamic Light Scattering (DLS), nanoDSF, and Flow Cytometry, supported by BSL1/BSL2 cell culture facilities.
Differentiator
Problem solved
Functional benefit
Brands
- FORMOscreen: 96 pre-made buffer conditions for rapid antibody characterization and formulation development, derived from FDA and EMA approved therapeutic antibody formulations
- BufferToolbox
- Qick'n'Tidy
- Signature Buffers
- 2bind BufferToolbox
Products and services
- Integrated Small Molecule Drug Discovery Services End-to-end preclinical discovery support for small molecule therapeutics, spanning protein target purification, hit identification, hit validation, and hit-to-lead optimization. Delivered as milestone-based projects with rapid turnaround (1-2 days to 2 weeks) for biotech and pharma sponsors. Covers chemical modalities including compounds, fragments, covalent small molecules, PROTACs/glues/RIPTAcs/multispecifics, peptides, and macrocycles, and target classes including globular proteins, intrinsically disordered proteins, membrane proteins, multiprotein complexes, RNAs, transcription factors, DNA and aptamers.
- Integrated Antibody Development Services Integrated antibody development services spanning screening, lead selection, lead candidate risk assessment and mitigation, developability assessment, preformulation, and storage stability studies, supported by BSL-1/BSL-2 cell culture capabilities. Covers antibody modalities including IgG1/IgG2/IgG4/Fc-silenced IgG, bispecifics, multispecifics, VHH/Nanobodies, scFvs, Fabs, antibody-fusion proteins, and ADCs.
- Stand-Alone Small Molecule Drug Discovery Services Flexible stand-alone biophysical services for clients pursuing independent small molecule drug discovery programs, including protein target purification, binding assessments and screening, in-depth characterization, and physicochemical/stability assessments.
- Stand-Alone Antibody Development Services Targeted stand-alone analyses for antibody programs, including binding assessments, screening, affinity ranking and in-depth characterization, physicochemical and developability assessments, storage stability, functional assays, and preformulation studies.
- FORMOscreen® 96-well pre-made buffer plate kit based on FDA- and EMA-approved therapeutic antibody formulations, designed for rapid antibody stability screening and preformulation development. Part of the 2bind BufferToolbox® series.
- Single-Cell Interaction Cytometry (scIC) Service Proprietary cell-based method for measuring binding kinetics (kon, koff, KD, avidity) directly on intact living or fixed cells under near-physiological conditions using the heliXcyto platform. No target purification is required, preserving the native membrane environment for difficult targets such as GPCRs, ion channels, and transporters.
Quantifiable outcome
- Rapid turnaround times of 1-2 days up to 2 weeks maximum for most projects
- +2 more outcomes
Companies that use 2bind
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
2bind technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature10 records
2bind partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core.
- CNATM (Cluster for Nucleic Acid Therapeutics Munich)coreIndustry partner in CNATM consortium for second funding period (2026-2029). 2bind contributes to development of scalable platform for production and biophysical characterization of lncRNA-binding proteins, aiming to identify and validate protein:RNA complexes as therapeutic targets. Funded by BMBF.
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)coreCOVID-19 drug discovery collaboration: project developing novel drug targeting SARS-CoV-2 nucleocapsid protein. Fraunhofer ITEM provides high-throughput cellular screening; 2bind provides biophysical analysis; University of Regensburg provides virology expertise.
- HIVacToGC ConsortiumcoreBMBF-funded interdisciplinary research project (2.4 million EUR) developing prophylactic HIV vaccine using DNA origami nanoparticles. Consortium includes University of Regensburg, TU Munich, Helmholtz Zentrum München, and tilibit GmbH. 2bind contributes biologics analytics and formulation development.
- Jena Bioscience GmbHcoreManufacturing partnership for FORMOscreen® production under ISO 9001 quality standards. Jena Bioscience manufactures the product, 2bind develops and markets it. FORMOscreen® distributed through Jena Bioscience and 2bind's webshop.
- University of RegensburgcoreGATarget consortium: BMBF-funded project (750,000+ EUR) investigating glutamine amidotransferase as novel antibiotic drug targets. 2bind provides biophysical analysis; University provides protein-protein interaction expertise led by Prof. Dr. Reinhard Sterner.
- Idris Oncology B.V.coreEurostars consortium partner for cancer diagnostic tool development - detecting and analyzing circulating tumor cells (CTCs) from blood for personalized therapy monitoring. 2bind develops biophysical analytical methods for characterizing binding molecules.
- Assay.WorkscoreStrategic service partnership with shared laboratory space at BioPark Regensburg. Assay.Works provides 2bind clients access to cell-based and biochemical assays plus automated high-throughput screening (HTS). 2bind provides Assay.Works clients access to biophysical analysis services including molecular interaction studies.
- NanoTemper TechnologiescoreCertified service provider and Center of Excellence for NanoTemper instruments, specializing in nanoDSF and DLS technologies.
- Wyatt TechnologiescoreCertified for DLS (Dynamic Light Scattering) services by Wyatt Technologies.
- Dynamics BiosensorscoreCertified service provider for heliX® and heliXcyto® technology platforms (optical detection + microfluidics for molecular interaction analysis).
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
2bind competitors and assessment
Company assessmentDirect peers
- Proteros biostructures GmbH: Germany-based preclinical CRO specializing in structure-based drug discovery, biophysics, and protein:ligand interaction analyses — the closest direct competitor to 2bind in the small-molecule biophysical characterization niche.
- Reaction Biology Corp: U.S. preclinical CRO offering biophysics, biochemical and cell-based assays for drug discovery, including SPR, ITC, and thermal shift services — directly overlapping 2bind's small molecule discovery service line.
- Creative Biolabs: Specialized CRO offering antibody discovery, characterization, developability, and formulation services — a direct competitor for 2bind's Antibody Unit across screening, lead selection, and preformulation.
Broad incumbents
- Eurofins Discovery: Global CRO network with broad preclinical discovery services including biophysics, DMPK, in vitro pharmacology, and formulation — overlaps with 2bind but operates at much larger scale with integrated end-to-end programs.
- Evotec SE: Hamburg-based integrated discovery and development CRO offering small molecule and biologics services from hit ID through IND — same German biotech ecosystem and same target customer base as 2bind, but at enterprise scale.
- Charles River Laboratories: Large global CRO providing discovery, safety assessment, and biopharma services including biophysical characterization and antibody developability — competes for the same biotech and pharma R&D budgets as 2bind but bundles biophysics into integrated programs.
- GenScript ProBio: Biologics CDMO and CRO offering antibody discovery, cell line development, and biophysical characterization — overlaps with 2bind's antibody and biologics service lines but at significantly larger scale with global footprint.
- Bio-Techne: Large life sciences tools and services provider with antibody development, proteomics, and GMP biopharma services — competes with 2bind for biotech antibody developability budgets and offers packaged kits (e.g., ProteinSimple platforms) that overlap with some biophysics workflows.
Others
- NanoTemper Technologies: Manufacturer of MST, nanoDSF, and DLS instruments and certified service provider partner of 2bind — adjacent rather than competitive, but NanoTemper's own internal services and the platforms they sell to other CROs shape 2bind's differentiation.
- Dynamics Biosensors GmbH: Manufacturer of the heliX and heliXcyto switchSENSE platforms that 2bind uses as a certified service provider — same technology dependency relationship as NanoTemper, with potential downstream services overlap in switchSENSE-based binding kinetics.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
2bind social profiles
Digital presence2bind compliance and trust
Trust signalCompliance1 record
2bind financial estimates
Financial estimateRevenue estimate
Valuation estimate
2bind leadership team
Management profileNumber of profiles
Profiles5 records
2bind funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
2bind M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 2bind
What does 2bind do?
2bind is a preclinical biopharma Contract Research Organization (CRO) providing end-to-end and stand-alone biophysical characterization services for small molecule drug discovery (protein purification, hit identification, hit validation, hit-to-lead optimization) and antibody development (screening, lead selection, developability, preformulation, storage stability). Services leverage proprietary biophysical platforms including Single-Cell Interaction Cytometry (scIC), MST, GCI, BLI, ITC, DLS, nanoDSF, and Spectral Shift, supported by BSL-1/BSL-2 cell culture laboratories and ISO 9001:2015 quality management. The company also sells FORMOscreen® pre-made buffer plates directly and via Jena Bioscience.
Is 2bind a public or private company?
2bind is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 2bind founded?
2bind was founded in 2017. It employs 11 to 50 people.
Where is 2bind based?
2bind is headquartered in Regensburg, Germany, in the Europe region.
How does 2bind make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are FORMOscreen® Product Sales.
Who are 2bind's main competitors?
Direct peers on record are Proteros biostructures GmbH, Reaction Biology Corp and Creative Biolabs. Broad incumbents are Eurofins Discovery, Evotec SE, Charles River Laboratories, GenScript ProBio and Bio-Techne. Others are NanoTemper Technologies and Dynamics Biosensors GmbH.
Does 2bind have an API?
No public API is recorded for 2bind.
What industry is 2bind in?
2bind's product category is Biopharma Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 541714 and its SIC code is 8731.